Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

The Selective SMARCA2 Degrader, PRT3789, Counteracts the Protective Cellular Stress Response to Chemotherapy and Enhances the Efficacy of Standard of Care Chemotherapeutic Agents in SMARCA4 Mutant NSCLC Models

Wednesday, October 23, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses PRT3789, a selective SMARCA2 degrader, which has been shown to counteract the protective cellular stress response to chemotherapy. This compound enhances the efficacy of standard chemotherapeutic agents in models of non-small cell lung cancer (NSCLC) with SMARCA4 mutations. The findings suggest a potential new avenue for improving treatment outcomes in affected patients.
Price reaction · baseline $1.75 (2024-10-23T13:37:00.000Z) · hit during market hours · 3 other PRLD headline(s) in the window, move may be shared
day 0 close
-6.3%
day 1
-11.4%
day 3 · peak
-14.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRT3789 shows promise in enhancing chemotherapy efficacy.
  • Targets SMARCA2, potentially improving treatment for NSCLC.
  • Could lead to better outcomes for patients with SMARCA4 mutations.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

• About Overview Leadership Board of Directors
• Science Overview Pipeline JAK2V617F KAT6A Precision DACs Discovery Engine Publications
• Investors Overview News & Events News Releases Events & Presentations Financials SEC Filings Quarterly Results Stock Information Stock Quote & Chart Analysts Governance Governance Documents Leadership Committee Composition Investor Resources Investor Faqs Contact IR Email Alerts
• News
• Life at Prelude Overview Open Positions
• Contact
• Overview
• Leadership
• Board of Directors
• Overview
• Pipeline
• JAK2V617F
• KAT6A
• Precision DACs
• Discovery Engine
• Publications
• Overview
• News & Events News Releases Events & Presentations
• Financials SEC Filings Quarterly Results
• Stock Information Stock Quote & Chart Analysts
• Governance Governance Documents Leadership Committee Composition
• Investor Resources Investor Faqs Contact IR Email Alerts
• News Releases
• Events & Presentations
• SEC Filings
• Quarterly Results
• Stock Quote & Chart
• Analysts
• Governance Documents
• Leadership
• Committee Composition
• Investor Faqs
• Contact IR
• Email Alerts
• Overview
• Open Positions
Michael Hulse, Jessica Burtell, Komali Vykuntam, Sang Hyun Lee, Peggy Scherle and Koichi Ito

Frequently Asked Questions

What is PRT3789?

PRT3789 is a selective SMARCA2 degrader designed to enhance chemotherapy efficacy.

How does PRT3789 affect chemotherapy?

It counteracts the protective cellular stress response, improving the effectiveness of standard chemotherapeutic agents.

In which cancer models was PRT3789 tested?

PRT3789 was tested in non-small cell lung cancer (NSCLC) models with SMARCA4 mutations.

What potential does PRT3789 have for patients?

It may lead to better treatment outcomes for patients with SMARCA4 mutations.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT3789 SMARCA2 NSCLC chemotherapy oncology
Last updated: Oct 23, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →